CN Patent

CN108727401A — 达鲁那韦新晶型及其制备方法和应用

Assigned to Yancheng Desano Pharmaceutical Co Ltd · Expires 2018-11-02 · 8y expired

What this patent protects

本发明涉及一种达鲁那韦新晶型及其制备方法和应用，具体地，本发明涉及[(1S,2R)‑3‑[[(4‑氨基苯基)磺酰基](2‑甲基丙基)氨基]‑2‑羟基‑1‑(苯基甲基)丙基]‑氨基甲酸(3R,3aS,6aS)六氢呋喃并[2,3‑b]呋喃‑3‑基酯的新晶型及其制备方法，所述晶型稳定，易于保存，且流动性更好，并且制备方法简单，可工业应用，具有广阔的药物前景。

USPTO Abstract

本发明涉及一种达鲁那韦新晶型及其制备方法和应用，具体地，本发明涉及[(1S,2R)‑3‑[[(4‑氨基苯基)磺酰基](2‑甲基丙基)氨基]‑2‑羟基‑1‑(苯基甲基)丙基]‑氨基甲酸(3R,3aS,6aS)六氢呋喃并[2,3‑b]呋喃‑3‑基酯的新晶型及其制备方法，所述晶型稳定，易于保存，且流动性更好，并且制备方法简单，可工业应用，具有广阔的药物前景。

Drugs covered by this patent

Patent Metadata

Patent number
CN108727401A
Jurisdiction
CN
Classification
—
Expires
2018-11-02
Drug substance claim
No
Drug product claim
No
Assignee
Yancheng Desano Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.